Tag: Simcyp
PBPK Modeling of Negative Food Effects upon Oral Drug Absorption of the BCS Class III Drug Trospium Chloride: Combination of a Dynamic Viscosity-disintegration Model and the ADAM (Advanced Dissolution, Absorption and Metabolism) Model
Use of a Minimal PBPK Model to Investigate the Effect of Shed Antigen on Simulated Trastuzumab in Humans
Simcyp In Vitro Analysis Toolkit (SIVA Toolkit)
Feasibility Assessment of PBPK Modeling for Endogenous Compounds: Baseline Levels of Endogenous Compounds in the Caucasian Population
Simcyp In Vitro Analysis Toolkit (SIVA Toolkit) A User-friendly Tool for Analysis of Complex In Vitro Experimental Data
Application of Permeability-limited Physiologically-based Pharmacokinetic Models: Part I—Digoxin Pharmacokinetic Incorporating P-glycoprotein-mediated Efflux
A prerequisite for the prediction of the magnitude of P-glycoprotein (P-gp)-mediated drug-drug interactions between digoxin and P-gp inhibitors (e.g. verapamil and its metabolite norverapamil) or P-gp inducers (e.g. rifampicin) is a predictive pharmacokinetic model for digoxin itself. Thus, relevant in vitro metabolic, transporter and inhibitory data incorporated into permeability-limited models, such as the “advanced dissolution, … Continued
Application of Permeability-limited Physiologically-based Pharmacokinetic Models: Part II—Prediction of P-glycoprotein Mediated Drug-drug Interactions with Digoxin
Digoxin is the recommended substrate for assessment of P-glycoprotein (P-gp)-mediated drug-drug interactions (DDIs) in vivo. The overall aim of our study was to investigate the inhibitory potential of both verapamil and norverapamil on the P-gp-mediated efflux of digoxin in both gut and liver. Therefore, a physiologically-based pharmacokinetic (PBPK) model for verapamil and its primary metabolite … Continued
Simcyp Releases Version 13 of its Widely Used Simulator
New release further expands biologics capabilities and provides new tools for formulation scientists ST. LOUIS, MO – Aug. 28, 2013 – Certara™, a leading provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through drug development, today announced that version 13 of its Simcyp™ Simulator has now been released, … Continued
Certara Launches Cardiac Safety Simulator to Help Assess New Drug Candidates’ Arrhythmia Risk
Simulator helps sponsors to assess arrhythmia risk before a candidate enters clinical trials; determine safe drug doses for specific patient populations ST. LOUIS, MO – August 1, 2013 Certara™, a leading provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through drug development, today announced the launch of its Cardiac … Continued